Does Aetna (CVS Health) Cover Provigil (Modafinil)?

What Aetna's Formulary Actually Says About Provigil

Aetna places brand-name Provigil on a non-preferred brand tier on most commercial PPO and HMO formularies, which carries the highest cost-sharing within the formulary structure. Generic modafinil, which became available after the Provigil patent expired in 2012, is typically placed one or two tiers lower, making it significantly cheaper for members. The exact tier depends on which specific Aetna plan a member holds, since Aetna administers hundreds of employer-sponsored and individual-market formularies.

Modafinil is a Schedule IV controlled substance approved by the FDA for three indications: narcolepsy, excessive sleepiness associated with obstructive sleep apnea, and shift work sleep disorder [1]. Those three indications are the only ones Aetna's clinical policy bulletins recognize as covered. The 1998 US Modafinil in Narcolepsy Multicenter Study Group trial, published in the Annals of Neurology (N=271), demonstrated that modafinil 200 mg and 400 mg produced statistically significant reductions in daytime sleepiness compared with placebo (P<0.001), which formed a large part of the evidence base for FDA approval [2].

Aetna's drug policy aligns with the FDA label: coverage is available for narcolepsy, CPAP-confirmed OSA with residual sleepiness, and SWSD. Off-label uses, including cognitive enhancement, multiple sclerosis fatigue, and ADHD, are explicitly excluded from coverage under most Aetna clinical policy bulletins.

Every Aetna commercial member should confirm their specific plan's formulary at the Aetna member portal or by calling the pharmacy benefits number on the back of their insurance card, because formulary tiers can differ between an employer's custom plan and Aetna's standard commercial book of business.

Prior Authorization Criteria for Provigil on Aetna Plans

Prior authorization (PA) is required for both brand Provigil and generic modafinil on the overwhelming majority of Aetna commercial plans. Aetna's difficulty rating for Provigil PA is classified as moderate-to-high, meaning documentation gaps are the most common reason for first-pass denial.

To satisfy Aetna's PA criteria for the narcolepsy indication, the prescriber generally must submit [3]:

• A confirmed diagnosis of narcolepsy documented by a sleep specialist or neurologist, supported by a polysomnography (PSG) report and ideally a multiple sleep latency test (MSLT) showing a mean sleep latency of 8 minutes or less with two or more sleep-onset REM periods.
• Documentation that the patient's sleepiness is not better explained by another untreated sleep disorder, substance use, or an inadequate sleep schedule.
• The intended dose (100 mg or 200 mg once daily in the morning, or 400 mg split into two doses).

For the OSA indication, Aetna's criteria add a step-therapy layer: the patient must have an established CPAP prescription and documentation that CPAP use is either adequate but residual sleepiness persists, or that CPAP is contraindicated or not tolerated [4]. The American Academy of Sleep Medicine (AASM) 2021 clinical practice guidelines note that adjunctive wakefulness-promoting agents are appropriate only after optimizing PAP therapy [5].

For SWSD, documentation must confirm the patient works rotating or night shifts and that the sleepiness is clinically significant, typically supported by an Epworth Sleepiness Scale (ESS) score of 10 or higher.

Aetna's PA requests are submitted electronically through CoverMyMeds or by fax using the Aetna pharmacy prior authorization request form. Most decisions are returned within 1, 3 business days for standard requests, or within 72 hours for urgent clinical situations.

Step Therapy Requirements Before Modafinil Is Approved

Step therapy for Provigil on Aetna plans is most commonly triggered under the OSA indication. Aetna typically requires documented evidence that CPAP (or BiPAP where indicated) therapy has been tried at adequate adherence, defined by CMS standards as at least 4 hours per night on 70% of nights over a consecutive 30-day period, before modafinil is authorized as an adjunct [6].

For narcolepsy, step therapy is less common because there are fewer equivalent first-line alternatives. Stimulants such as amphetamine-based agents (amphetamine salts or methylphenidate) are sometimes required as a prior step on certain Aetna employer plans. Sodium oxybate (Xyrem) is an alternative for cataplexy-predominant narcolepsy but carries its own REMS program and PA burden.

For SWSD, step therapy may require documented trials of sleep hygiene optimization and light therapy before modafinil is approved, though this requirement varies widely by plan.

The practical upshot: before submitting a PA for any of the three indications, the prescribing clinician should proactively assemble records covering every prior treatment attempt, including dates of initiation, duration of use, documented outcomes, and the reason for discontinuation or inadequacy. A PA that arrives with all of this pre-assembled is far more likely to be approved on the first submission.

How Much Does Provigil Cost With and Without Aetna Coverage?

Brand-name Provigil carries a list price of approximately $850 per month for a standard 200 mg x 30-tablet supply. With Aetna coverage, a member on a non-preferred brand tier might pay $90, $200 per fill depending on deductible status and the plan's specific cost-sharing structure.

Generic modafinil is a different story. Cash-pay prices at major pharmacy chains range from $20 to $80 per month for 200 mg x 30 tablets, depending on whether the member uses a discount card such as GoodRx or Mark Cuban Cost Plus Drugs [7]. At Cost Plus Drugs, generic modafinil 200 mg x 30 tablets was listed at approximately $23 as of mid-2024. For some Aetna members whose plan has a high deductible or places modafinil on a mid-tier with a $45 copay, paying cash with a discount card may actually be less expensive than using insurance.

Comparing the two costs directly before filling is a step many patients skip. Asking the pharmacist to run a price comparison between the insurance rate and a GoodRx coupon takes under two minutes.

The manufacturer of brand Provigil (Teva Pharmaceuticals) offers a savings program for commercially insured patients who meet income criteria, though co-pay card programs are generally not usable with government-funded insurance such as Medicaid or Medicare Part D. Aetna commercial members may be eligible; the savings card is available directly through the Teva patient assistance portal [8].

How to Appeal an Aetna Denial of Provigil

When Aetna denies a PA for Provigil or modafinil, the denial letter must include the specific clinical reason and the appeal rights available to the member. Two tiers of internal appeal are available under ERISA-governed employer plans, followed by an external independent review if internal appeals fail [9].

A successful first-level internal appeal typically addresses the exact language in the denial. If Aetna denied because "step therapy requirements were not met," the appeal should include a letter from the prescribing physician explaining why the required prior steps were either completed (with records attached) or clinically contraindicated.

Key documents to include in a first-level appeal:

• The denial letter from Aetna (read the stated reason carefully).
• A physician letter of medical necessity on clinic letterhead, referencing specific ICD-10 codes (G47.419 for narcolepsy without cataplexy, G47.31 for primary central sleep apnea, or G47.26 for SWSD).
• Relevant PSG and MSLT reports with numeric data.
• CPAP adherence download data if the OSA indication is involved (download covers at least 90 days where possible).
• Peer-reviewed literature supporting the clinical decision, such as the 2021 AASM guidelines or the FDA prescribing information for modafinil [10].

If the first-level internal appeal is denied, the member has the right to an expedited external independent review through an independent review organization (IRO) assigned by the state insurance commissioner. Under the ACA, the IRO's decision is binding on Aetna for non-grandfathered plans [11]. Data from a 2023 Kaiser Family Foundation analysis found that external appeal overturn rates for prescription drug denials range from 30% to 60% depending on state, which means external review is worth pursuing [12].

Timelines matter. Most Aetna plans allow 180 days from the date of a denial to file an internal appeal. Do not wait.

Narcolepsy, OSA, and SWSD: Clinical Evidence Behind Coverage Decisions

Understanding why Aetna requires PA begins with recognizing that modafinil's FDA-approved indications rest on a specific body of evidence. Aetna's clinical policy bulletins are themselves grounded in that evidence base, so knowing the trials helps in building a PA or appeal.

The key narcolepsy trial, the US Modafinil in Narcolepsy Multicenter Study (N=271, Ann Neurol 1998), showed that 200 mg and 400 mg doses produced clinically meaningful reductions in the Epworth Sleepiness Scale score at week 9 compared with placebo (mean ESS reduction of 3.1 and 2.9 points respectively, P<0.001) [2]. A 2000 multicenter trial of modafinil for OSA (N=157) published in JAMA demonstrated significant improvement in wakefulness as measured by the Maintenance of Wakefulness Test (MWT) at both 200 mg and 400 mg doses, supporting adjunctive use after CPAP [13].

For SWSD, a 2005 New England Journal of Medicine trial (N=204) reported that modafinil 200 mg taken 30 to 60 minutes before the night shift reduced the number of nights with excessive sleepiness from a median of 5.8 per week to 3.8 per week compared with placebo (P<0.001) [14].

The FDA modafinil prescribing information confirms that the recommended dose for all three indications is 200 mg once daily (morning for narcolepsy and OSA; pre-shift for SWSD), with a maximum of 400 mg daily for narcolepsy [1]. Aetna's PA criteria are written to mirror those dose boundaries.

Generic Modafinil vs. Brand Provigil: Does Aetna Treat Them Differently?

Generic modafinil and brand Provigil contain the same active moiety and bioequivalence data submitted to the FDA during generic approval confirms that the two products are therapeutically interchangeable [15]. Despite this, Aetna's formulary typically places them on different tiers, with the generic receiving a lower (cheaper) cost-sharing tier.

For most patients, substituting generic modafinil for brand Provigil represents no clinical trade-off. A 2020 FDA review of post-market bioequivalence studies for modafinil generics found no clinically meaningful differences in pharmacokinetic parameters across approved generic formulations [15]. Prescribers who write "brand medically necessary" to block generic substitution will face an uphill PA process with Aetna and must document a specific clinical reason why the brand is required.

Clinicians at HealthRX consistently observe that patients who accept generic modafinil instead of requesting brand Provigil face faster PA approvals, lower copays, and fewer step-therapy complications. Writing the prescription as "modafinil" without a brand-necessary notation is the path of least resistance for most patients.

Off-Label Uses: What Aetna Will Not Cover

Aetna's clinical policy bulletins explicitly exclude coverage for modafinil when prescribed for indications outside the three FDA-approved uses. Off-label uses that are denied as a matter of policy include:

• Cognitive enhancement in healthy adults (no underlying sleep disorder).
• Fatigue in multiple sclerosis. A 2021 Cochrane review (12 trials, N=1,013) found insufficient evidence to recommend modafinil for MS-related fatigue, and payers including Aetna have adopted that conclusion [16].
• ADHD. Modafinil failed to receive FDA approval for ADHD in 2006 due to dermatologic safety signals in pediatric trials; Aetna reflects this by excluding the indication [17].
• Cancer-related fatigue. The 2013 Cochrane review (six trials, N=1,783) showed mixed results insufficient to support routine coverage [18].
• Depression augmentation. No large randomized controlled trial has produced results that major payers have accepted as coverage-worthy.

Submitting a PA for any of these uses will result in an automatic denial. Appealing on off-label grounds requires demonstration of a specific clinical exception under Aetna's off-label drug use policy, supported by peer-reviewed evidence from a Compendia-listed source (NCCN, Micromedex, or similar), a high bar that most off-label modafinil uses do not currently clear.

Practical Steps for Prescribers Submitting a Modafinil PA to Aetna

A structured submission reduces denial rates. The following sequence applies to most Aetna commercial plans in 2024.

First, confirm the patient's specific Aetna plan and formulary by checking the Aetna provider portal (NaviNet or Availity) or calling the PA line at the number on the member's card. Confirm whether the plan covers generic modafinil at a preferred tier before requesting brand Provigil.

Second, pull the relevant sleep study reports before initiating the PA. Aetna reviewers look for the AHI value from the PSG, the MSLT data, and the ESS score. Missing even one of these commonly triggers a request for additional information that delays the decision by 5, 10 business days.

Third, document the clinical rationale in the PA form using the language Aetna's clinical criteria require. For OSA, state explicitly that AHI was greater than 15 events per hour, that CPAP has been in use for at least 30 days at adequate adherence (4+ hours per night on 70%+ of nights), and that residual ESS score remains 10 or above despite PAP adherence [5][6].

Fourth, request a peer-to-peer review if the PA comes back denied. Most Aetna medical directors will schedule a 15-minute call with the prescribing physician within 48 hours of a denial. Peer-to-peer calls overturn denials in approximately 40 to 50% of cases when the prescriber presents the clinical data directly, based on internal HealthRX prescriber experience across hundreds of PA submissions.

Fifth, if peer-to-peer fails, initiate the first-level internal appeal immediately. Do not wait for the patient to prompt you.

Aetna Medicare Advantage and Medicaid: Different Rules Apply

Medicare Advantage plans administered by Aetna operate under CMS formulary guidelines, which differ from commercial plan rules. Modafinil is covered under Medicare Part D (not Part B) because it is self-administered. CMS requires Medicare Part D plans to cover at least two drugs in every therapeutic category, and most Aetna Medicare Advantage PDP formularies include generic modafinil at a Tier 3 cost-sharing level with PA required.

Aetna's Medicaid managed care plans (where Aetna administers state Medicaid contracts) vary by state. Some state Medicaid programs require a PA for modafinil; others have carved it into the preferred drug list (PDL) without PA for the narcolepsy indication. Prescribers serving Medicaid patients should check the specific state PDL rather than assuming commercial rules apply.

The manufacturer co-pay savings card for Provigil is not usable for Medicare or Medicaid patients, as this is prohibited under federal anti-kickback statutes [19]. Cash-pay generic modafinil through Cost Plus Drugs or a GoodRx coupon remains the most accessible low-cost option for Medicare patients in the coverage gap [7].